Sherman, M. Et Al. 2008. Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologie, biochemical, and serology outcomes through 96 weeks. Hepatology , vol.48, no.1 , 99-108.

Sherman, M., Yurdaydin, C., Simsek, H., Silva, M., Liaw, Y., Rustgi, V. K., ... Sette, H.(2008). Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologie, biochemical, and serology outcomes through 96 weeks. Hepatology , vol.48, no.1, 99-108.

Sherman, Morris Et Al. "Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologie, biochemical, and serology outcomes through 96 weeks," Hepatology , vol.48, no.1, 99-108, 2008

Sherman, Morris Et Al. "Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologie, biochemical, and serology outcomes through 96 weeks." Hepatology , vol.48, no.1, pp.99-108, 2008

Sherman, M. Et Al. (2008) . "Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologie, biochemical, and serology outcomes through 96 weeks." Hepatology , vol.48, no.1, pp.99-108.

@article{article, author={Morris Sherman Et Al. }, title={Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologie, biochemical, and serology outcomes through 96 weeks}, journal={Hepatology}, year=2008, pages={99-108} }